Antares Pharma (ATRS) Received its Third Buy in a Row

By Carrie Williams

After Jefferies and Raymond James gave Antares Pharma (NASDAQ: ATRS) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Oren Livnat maintained a Buy rating on Antares Pharma today and set a price target of $4.50. The company’s shares closed on Friday at $3.37.

According to TipRanks.com, Livnat is a 4-star analyst with an average return of 5.7% and a 51.0% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Verrica Pharmaceuticals Inc, Taiwan Liposome Company Ltd, and Pacira Pharmaceuticals.

Antares Pharma has an analyst consensus of Strong Buy, with a price target consensus of $9.73, implying a 188.7% upside from current levels. In a report issued on February 25, Cowen & Co. also initiated coverage with a Buy rating on the stock with a $7 price target.

See today’s analyst top recommended stocks >>

Based on Antares Pharma’s latest earnings release for the quarter ending December 31, the company reported a quarterly net profit of $6.13 million. In comparison, last year the company had a GAAP net loss of $3.71 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Antares Pharma, Inc. is a pharmaceutical company. The company focuses on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. Its activities include the development of injection devices and injection based pharmaceutical products as well as transdermal gel products.